AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03279679 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: 0.5% ropivacaine will be used for the brachial plexus block in both groups.
Study NCT02508961 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: web-based physio exercise programme
Study NCT02508961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: web-based physio exercise programme
Study NCT05409677 — intervention group
Intervention type: OTHER
Intervention: This was a retrospective study with no intervention other than normal treatment
Description: This was a retrospective study with no intervention other than normal treatment
Study NCT02407379 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PAPD+SRP
Description: Photoablation of the gingival epithelium was performed with at 810 nm diode laser (1 W output power, continuous wave mode, 66.7 J/cm2, a 0.6 mm optical fiber). SRP was performed using curettes. The periodontal tissues and the dental root were rinsed with the photosensitizer agent methylene blue (0.3% w/v in water). After 5 min., the treated areas were irradiated with at 635 nm diode laser (100 mW output power, continuous wave mode, 0.6 mm optic fiber). The photodynamic treatment was repeated once weekly until normalization of the cytodiagnostic parameters (range: 4-10 applications).
Study NCT02407379 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-laser +SRP
Description: Sham-treatment was similar to the previously described treatment but with switched off laser, followed by scaling and root planing
Study NCT04807114 — intervention group
Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: Standard-of-care treatment for st.IV NSCLC (no driver mutation, PD-L1 > 50%)
Study NCT04807114 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy + Immune checkpoint inhibitor
Description: Standard-of-care treatment for st.IV NSCLC (no driver mutation, PD-L1 \< 50%)
Study NCT01625156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01625156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01625156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT01625156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Given PO
Study NCT00194740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg/m2, IV, day 1 of each 21 day cycle
Study NCT00194740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: 27.5 mg/m2, IV, days 8 \& 15 of each 21 day cycle
Study NCT00194740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 µg/kg/day s.c., to be administered days 2-21 of each cycle.
Study NCT02018146 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mask then nasopharyngeal
Description: Patients will be randomly assigned to Mask ventilation followed by naso-pharyngeal ventilation
Study NCT02018146 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nasopharyngeal then mask
Description: Patients will be randomly assigned to naso-pharyngeal ventilation followed by mask ventilation.
Study NCT06428994 — intervention group
Intervention type: RADIATION
Intervention: Radiotherapy
Description: Post-operative radiotherapy for head and neck cancer
Study NCT03035916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Description: Participants in this group receive ultrasound-guided TAP block under bilateral costal margin with multiple injections of 40ml 0.375% ropivacaine after the induction of general anesthesia, 30 minutes later the surgery will be started.
Study NCT03035916 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidural anesthesia
Description: Participants in the Epidural group receive a epidural block (T8-9) with 2 mL of 1.6% lidocaine as a test dose before induction. After a successful placement of epidural catheter, the block then is established with 5 mL of 0.375% ropivacaine and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery.
Study NCT03035916 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: The Control group receives standard IV-inhaled general anesthesia.
Study NCT02636803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxfendazole
Description: group receives a single dose of oxfendazole at 6 or 30 mg/kg or three 6 mg/kg doses
Study NCT02636803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole
Description: group receives one 400 mg dose of albendazole
Study NCT02895139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Additive Manufactured Orthotic Device
Description: The 3D foot scan data will be used to generate a 3D model of the foot orthotic which will then be adapted to be suitable for solid printing. The final model will be saved in .stl format for use in the printing software. The additive manufactured orthotic insoles and all features or additions will be produced in a single build from additive materials matched for hardness to medium density EVA. Post production the orthotic will be cleaned to remove support material and a top cover will be attached to the final additive manufactured orthotic insole.
Study NCT02895139 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Moulded orthotic
Description: The foam impression box and prescription will be sent to an external company for production of the handmade moulded orthotics. Handmade moulded orthotics will be produced by heating and wrapping medium density Ethylene-vinyl acetate (EVA) around plaster casts of the impression boxes. The orthotic insoles may be manually adapted to meet the requirements of the prescription, this could include cut out sections designed to offload regions of the foot or the addition of features such as metatarsal bars which provide varied support. Features and additions will be added in post manually by cutting and gluing onto the moulded orthotic insole. A top cover will be attached to the final moulded orthotic insole.
Study NCT02895139 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Milled orthotic
Description: The 3D foot scan data will be used to generate a 3D model of the foot orthotic. This will then be saved in .pan format for use in a CNC milling software. Orthotics and all features will be milled in a single mill from a block of medium density EVA. Post milling the orthotics will be cleaned. The orthotic insoles may be manually adapted to meet the requirements of the prescription, this could include cut out sections designed to offload regions of the foot or the addition of features such as metatarsal bars which provide varied support. Features and additions will be added in post manually by cutting and gluing onto the milled orthotic insole. A top cover will be attached to the final milled orthotic insole.
Study NCT04498598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A/Z Supraglottic airway
Description: Patient receive supraglottic airway for general anesthesia which can be converted to endotracheal ventilation reversibly
Study NCT02006056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Patients will take Ondissolve (8mg) on the day of the radiation treatment at least one hour prior to treatment and repeat approximately 6-8 hours later in the day (bid). For patients who are being treated with 20Gy in 5 fractions, or 30 Gy in 10 fractions, this group will take Ondissolve twice (bid) on each day of treatment, at least 1 hour prior to treatment and also on weekends or holidays in between treatment.
Study NCT02577627 — intervention group
Intervention type: DEVICE
Intervention: PrediCare
Study NCT03419130 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated RT
Study NCT03419130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03419130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03419130 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo conventionally fractionated RT
Study NCT03851978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist Vaccine Education
Description: When an eligible patient presents to the pharmacy for prescription pick up or drop off, the pop-up note will notify the technician to get a pharmacist for education. The pharmacist will educate the patient on the vaccine and then recommend that the patient receives the vaccine.
Study NCT03887429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXC-2023
Description: SXC-2023 oral capsules
Study NCT03887429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Matching Placebo oral capsules
Study NCT02585687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: liver Perfusion MRI
Study NCT02584959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor [human] liquid
Description: C1 Esterase Inhibitor \[Human\] Liquid administered Subcutaneously as specified on specified days
Study NCT02584959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01250353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pterygium surgery
Description: pterygium was removed surgically
Study NCT00987597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technique of in-vivo exposure (cigarette) and mental image exposure (craving)
Description: Nicotine replacement
Study NCT00987597 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional follow-up
Description: nicotinic substitutes
Study NCT03986229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluate the variation in the travel speed of the center of pressure with and without compression garments.
Description: Each evaluation will be done according to the following protocol:~* Evaluation of the pain~* Berg test~* One test per condition starting with open eyes~* Standardized instructions:~* Break about 15 minutes (wash-out) between each test.~* Both conditions will be tested on the same day.~* Evaluation in an environment free from visual and audible interference.
Study NCT03131700 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPH001
Description: Avastin® has been approved for treatment of various cancers in many countries of the world including the USA, EU countries, and Turkey. In Turkey, Avastin® is approved with a different trade name, Altuzan®, for treatment of metastatic colorectal cancer.
Study NCT03131700 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Avastin®
Description: R-Pharm created a biological analog of Avastin®, RPH-001. RPH-001 and Avastin® have similar physicochemical properties, pharmacokinetic profile and affinity to human vascular endothelial growth factor, similar toxicity and efficacy confirmed by preclinical study results.
Study NCT01267825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-guided corticosteroid+ bupivicaine
Description: CT-guided corticosteroid+ bupivicaine Also get standard medical care
Study NCT01267825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical care
Description: Naproxen + Oxycodone/ Acetaminophen
Study NCT04256213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab
Description: Nivolumab, IV D1C1 and D15C1 (before RT-CT) at 3 mg/kg Every 28 days at 480 mg during 6 months after RT-CT~Ipilimumab, 1 mg/kg, IV D1C1 (before RT-CT)
Study NCT01869569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: At the 4-week dose-titration phase, will receive one capsule of pregabalin (75 mg) twice daily from Day 1 to Day 7, and two capsules of pregabalin (150 mg) twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of pregabalin.
Study NCT01869569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At the 4-week dose-titration phase, will receive one capsule of placebo twice daily from Day 1 to Day 7, and two capsules of placebo twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of placebo.
Study NCT04052360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod
Description: A single oral dose of 4 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
Study NCT04052360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: A single oral dose of matching placebo will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
Study NCT04150705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDG PET/MRI
Description: -All patients will undergo a simultaneous list mode PET and MR acquisition beginning 55-65 minutes after administration of FDG according to a standard weight-based scale.
Study NCT04333225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Weekly treatment in individuals at high risk
Study NCT04786665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strawberry
Description: Freeze dried strawberry powder
Study NCT04786665 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Comparative placebo powder
Study NCT02958332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video game program
Description: Participants will use the Wii console and the Wii balance board, to play different video games which imply shoulder movements. They will receive 5 individual sessions of 30 minutes.
Study NCT02472626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-Bis(benzylthio)octanoic Acid
Description: Given IV
Study NCT02472626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT02472626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT04442438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monthly moral case deliberation
Description: Once per month, ICU professionals will take part in moral case deliberation. As part of the intervention, two or three ICU professionals (physicians and nurses) are tasked with selecting a case for moral discussion. Moral case deliberation is attended by around thirty individuals per month per unit. A feedback system will be developed used to spread the knowledge/insights from the case deliberation to all professionals in the unit.
Study NCT04442438 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Monthly moral case deliberation
Description: Once per month, ICU professionals will take part in moral case deliberation. As part of the intervention, two or three ICU professionals (physicians and nurses) are tasked with selecting a case for moral discussion. Moral case deliberation is attended by around thirty individuals per month per unit. A feedback system will be developed used to spread the knowledge/insights from the case deliberation to all professionals in the unit.
Study NCT01807728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 1 Training Program
Description: Up to four group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
Study NCT01807728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2 Training Program
Description: Two group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
Study NCT03963180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: coffee
Description: All patients were asked to drink the entire 150-mL amounts within 20 minutes under the supervision of a nurse or doctor. Patients were free to drink any amount of water but no more coffee, black tea, or other forms of caffeine, such as soda. Coffee and hot water were prepared with a conventional coffee machine (Nescafe Alegria; 100 g caffeine; Nestlé. Gatwick, United Kingdom).
Study NCT02742714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam SBC system
Description: The PillCam SBC system to be tested in this study, is a new system composed of capsule, Data recorder and a new software Pillcam Desktop Software (version 9.0). The main features of the SBC capsule are panoramic field of view and adaptive frame rate customized for complete coverage of both small bowel and colonic mucosa.
Study NCT01349933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt inhibitor MK2206
Description: Given PO
Study NCT03514979 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Polysaccharide Conjugate vaccination and Pneumococcal Polysaccharide Vaccination
Description: Pneumococcal vaccines
Study NCT03090451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic physical exercise on treadmill, with intensity based on prior VO2-max testing during the screening visit.
Study NCT02380859 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prism adaptation
Description: Prism adaptation is one type of sensorimotor adaptation. Prism adaptation described any adaptation to a prismatic shift in vision (i.e. any magnitude or direction of shift). In this study we are using adaptation to upward-shifting prisms, which induces a downward sensorimotor after-effect.
Study NCT02380859 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Prism adaptation
Description: Prism adaptation is one type of sensorimotor adaptation. Prism adaptation described any adaptation to a prismatic shift in vision (i.e. any magnitude or direction of shift). In this study we are using adaptation to upward-shifting prisms, which induces a downward sensorimotor after-effect.
Study NCT03887117 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IQOS + Exercise Training Program
Description: Switch to IQOS use + participation in a training program
Study NCT03887117 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IQOS without Exercise Training Program
Description: Switch to IQOS use only, without participation in a training program
Study NCT03887117 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette Smoking + Exercise Training Program
Description: Continue to smoke cigarettes + participation in a training program
Study NCT03887117 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Abstinence + Exercise Training Program
Description: Switch to smoking abstinence + participation in a training program
Study NCT02135705 — intervention group
Intervention type: DRUG
Intervention: Lomitapide
Description: As prescribed by Physician.
Study NCT03637530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inverse ratio ventilation
Description: during general anaesthesia in laparoscopic surgeries, this group of patients will receive inverse ratio ventilation with proper observation of hemodynamics
Study NCT02809508 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oily fish
Description: A selection of oily fish, including salmon, herring and mackerel, provided for dinner and lunch
Study NCT02809508 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Poultry
Description: A selection of poultry, mainly chicken, provided for dinner and lunch
Study NCT03045393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine (IMGN853)
Description: Mirvetuximab Soravtansine is a targeted drug for tumors that express high levels of folate receptor alpha.
Study NCT02790593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juxta-Cures™
Description: Juxta-CURES™ is an adjustable compression device, which may be used as a secondary dressing for the treatment of open venous stasis ulcers. It is an inelastic wrap around device with a Built-In-Pressure System™, which allows patients to easily and accurately apply pressure to their own leg and adjust it throughout the day.
Study NCT02790593 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Compression
Description: Compression bandaging
Study NCT02790593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoPress®
Description: Pressure monitoring to be done at time of bandage application and removal for both arms of the study.
Study NCT02790593 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PicoPress®
Description: Pressure monitoring to be done at time of bandage application and removal for both arms of the study.
Study NCT02790593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silhoutte® 3D wound imaging system
Description: Photographic imaging system to measure wound surface area and depth. Picture to be taken at each appointment. This intervention is for both arms of the study.
Study NCT02790593 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silhoutte® 3D wound imaging system
Description: Photographic imaging system to measure wound surface area and depth. Picture to be taken at each appointment. This intervention is for both arms of the study.
Study NCT01899118 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation
Description: 50.4Gy/28F/5.5w
Study NCT01899118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 400mg/w，0-5w